Zemplar and Pancytopenia - a phase IV clinical study of FDA data

Summary:

Pancytopenia is reported as a side effect among people who take Zemplar (paricalcitol), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Renagel, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Pancytopenia when taking Zemplar. It is created by eHealthMe based on reports of 15,456 people who have side effects when taking Zemplar from the FDA, and is updated regularly.

What is Zemplar?

Zemplar has active ingredients of paricalcitol. It is often used in kidney disease. eHealthMe is studying from 15,494 Zemplar users. Check the latest studies of Zemplar.

What is Pancytopenia?

Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets) is found to be associated with 1,792 drugs and 2,431 conditions by eHealthMe. Check the latest studies of Pancytopenia.

On Jul, 20, 2026

15,456 people reported to have side effects when taking Zemplar.
Among them, 20 people (0.13%) have Pancytopenia.

Among these 20 people:

How long have people been on Zemplar when they have Pancytopenia? *

What is the gender of people who have Pancytopenia when taking Zemplar? *

female: 70 %
male: 30 %

What is the age of people who have Pancytopenia when taking Zemplar? *

What are other drugs people take besides Zemplar? *

What are other side effects people have besides Pancytopenia? *

Thrombocytopenia (decrease of platelets in blood): 14 people, 70.00%
Chronic Renal Failure (kidney failure): 13 people, 65.00%
Dizziness: 13 people, 65.00%
Nausea And Vomiting: 12 people, 60.00%
Osteomyelitis (infection of bone): 12 people, 60.00%
Sepsis (a severe blood infection that can lead to organ failure and death): 12 people, 60.00%
Weakness: 11 people, 55.00%
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 10 people, 50.00%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 10 people, 50.00%
Pleural Effusion (water on the lungs): 10 people, 50.00%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 10 people, 50.00%
Pain: 9 people, 45.00%
Limb Discomfort (discomfort in leg): 9 people, 45.00%
Acute Kidney Failure: 9 people, 45.00%
Hyperparathyroidism Secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary): 3 people, 15.00%
Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood): 2 people, 10.00%
Hyperparathyroidism (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium): 2 people, 10.00%
Hepatitis C: 2 people, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Zemplar and have Pancytopenia?

- Check whether Pancytopenia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zemplar:

Zemplar (15,494 reports)

Pancytopenia treatments and more:

Pancytopenia (69,290 reports)

Browse all side effects of Zemplar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pancytopenia:

Pancytopenia (1,792 drugs)

Browse all the conditions that are associated with Pancytopenia:

Pancytopenia (2,431 conditions)

Related publications that referenced our studies

Ate? ?, Arikan MF, Kaplan M, Altay M, "Hydroxyzine induced pancytopenia and petechial rashes: a rare complication", Journal Of Contemporary Medicine, 2017 Jan .
Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .
Ate? ?, Arikan MF, Kaplan M, Altay M, "Hydroxyzine induced pancytopenia and petechial rashes: a rare complication", Journal Of Contemporary Medicine, 2017 Jan .
Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on paricalcitol (the active ingredients of Zemplar) and Zemplar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.